US lab products giant Beckman Coulter has successfully opposed an Australian biotech’s bid to trade mark ‘Cytophex’ for its stem cell expansion system, with an IP Australia delegate finding the mark is too similar to Beckman’s ‘CytoFLEX’ mark.
Payday lender Sunshine Loans has lost an appeal after it was ruled liable for “wrongheaded” conduct, with an appeals court finding that counsel showed an “egregious failure” to confine the case to the real issues.
The funder that backed a shareholder class action against engineering firm CIMIC that settled for $45.25 million will take a cut to its 25 per cent commission, but wants the court to find the commission would otherwise have been reasonable.
United Petroleum has successfully sued the landlords of one of its petrol stations for failing to pay for repairs to potholes described as “more like large craters”.
Another fight over an $87 million mixed-use Canberra development may be on the cards, after the project’s liquidators won approval to assign potential claims against WSP and builder Construction Control over alleged stitch bolt defects.
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis’ appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
A group member in a class action against Johnson & Johnson unit DePuy has filed an appeal after he lost a challenge to his compensation determination, 12 years after the case settled.
A judge has found that three directors at ASX-listed investment firm Keybridge Capital were validly removed and replaced at a meeting last month.
News Corp has agreed to removed posts that allegedly defamed a senior member of the Hells Angels bikie gang by labelling him a “cocaine kingpin” and “fugitive from justice”.
Former directors of collapsed Sydney developer Dyldam have been targeted by a liquidator over claims allegedly worth at least $33 million.